Author + information
- Benjamin Robert Szwejkowski,
- Stephen Gandy,
- Sushma Rekhraj,
- Houston Graeme,
- Jacob George,
- Lang C. Chim,
- Andrew D. Morris and
- Allan D. Struthers
Cardiovascular (CV) complications are the most important cause of mortality and morbidity in Type 2 Diabetes (T2DM). Left Ventricular Hypertrophy (LVH) is common in T2DM and contributes to this CV risk. LVH can be related to oxidative stress (OS) and allopurinol reduces OS. We therefore investigated whether allopurinol regresses LVH in patients with T2DM.
We conducted a randomised, double blind, placebo controlled study in 66 T2DM patients with echocardiographic evidence of LVH. Allopurinol 600mg/day or placebo was given for nine months over the study period. The primary outcome was reduction in left ventricular mass (LVM) as calculated by cardiac magnetic resonance imaging (MRI) at baseline and at nine months follow-up. The secondary end-points were change in flow mediated dilatation (FMD) and augmentation index (AIx).
Allopurinol significantly reduced absolute LVM (−2.65 ± 5.91g and placebo group +1.21 ± 5.10g (p=0.012)) and LVM indexed to body surface area (−1.32 ± 2.84g/m2and placebo group +0.65 ± 3.07g/m2(p=0.017)). No significant change was seen in both FMD and AIx.
Allopurinol regresses LVM in patients with T2DM and LVH. Regressing LVH has been shown previously to improve CV mortality and morbidity. Therefore allopurinol may be a useful therapy to reduce CV risk in T2DM patients with LVH.
Moderated Poster Contributions
Poster Sessions, Expo North
Sunday, March 10, 2013, 9:45 a.m.-10:30 a.m.
Session Title: Potential Ways to Improve Myocardial Function with Pre-Existing Therapies
Abstract Category: 23. Pericardial/Myocardial Disease
Presentation Number: 1206M-141
- 2013 American College of Cardiology Foundation